Fixed combination of shared cancer antigens

• Concept: Cancer immunotherapies targeting shared antigens that we have identified to be frequently expressed across patients with a specific cancer type.
• mRNA Format: Optimized mRNA providing superior immunogenicity.
• mRNA Delivery Formulation: Proprietary size- and charge-based RNA-LPX targeting DCs.
• Development Approach: Worldwide rights; wholly owned.
• Lead Candidate: BNT111 for metastatic melanoma.
• Data Highlights: Four partial responses and eight stable diseases in 22 patients with metastatic lesions at enrollment, following BNT111 monotherapy.

More about FixVac